MPL anticorps

N° du produit ABIN969542

Détail du produit anti-MPL anticorps

Antigène: MPL (Myeloproliferative Leukemia Virus Oncogene (MPL))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp MPL est non-conjugé

Application: ELISA, Flow Cytometry (FACS)

Fonction: MPL Antibody

Purification: Purified antibody

Immunogène: Purified recombinant fragment of human MPL expressed in E. Coli.

Clone: 1H2

Isotype: IgG2b

Information d'application

Indications d'application:

ELISA: 1/10000

FCM: 1/200 - 1/400

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified antibody in PBS with 0.05 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-MPL (ABIN969542)

Marty, Chaligné, Lacout, Constantinescu, Vainchenker, Villeval: "Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity." dans: The Journal of biological chemistry, Vol. 284, Issue 18, pp. 11781-91, (2009) (PubMed).

Blackford, Parmigiani, Kensler, Wolfgang, Jones, Zhang, Parsons, Lin, Leary, Eshleman, Goggins, Jaffee, Iacobuzio-Donahue, Maitra, Klein, Cameron, Olino, Schulick, Winter, Vogelstein, Velculescu, Kinzler, Hruban: "Genetic mutations associated with cigarette smoking in pancreatic cancer." dans: Cancer research, Vol. 69, Issue 8, pp. 3681-8, (2009) (PubMed).

Détails sur MPL

Antigène: MPL (Myeloproliferative Leukemia Virus Oncogene (MPL))

Autre désignation: MPL (MPL Produits)

Synonymes: anticorps C-MPL, anticorps CD110, anticorps MPLV, anticorps THCYT2, anticorps TPOR, anticorps TPO-R, anticorps c-mpl, anticorps c-mpl-I, anticorps c-mpl-II, anticorps hlb219, anticorps MPL, anticorps mpll, anticorps tpor, anticorps tpor.b, anticorps MPL proto-oncogene, thrombopoietin receptor, anticorps myeloproliferative leukemia virus oncogene, anticorps MPL, anticorps Mpl, anticorps mpl

Sujet:

Description: In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

Aliases: MPLV, TPOR, C-MPL, CD110

Poids moléculaire: 71.2kDa

ID gène: 4352

HGNC: 4352

UniProt: P40238

Pathways: Signalistation JAK/STAT